摘要
目的:探讨盆炎1号方经皮经穴靶向透药治疗在慢性盆腔炎(湿热瘀结型)患者治疗中的应用价值。方法:所有慢性盆腔炎(湿热瘀结型)患者均于2017年8月至2021年3月在海南省儋州市中医医院就诊并随机分组,对照组57例患者采用单纯西医治疗,观察组57例联合盆炎1号方经皮经穴靶向透药治疗,治疗3个月后比较疗效。结果:治疗后观察组血清基质金属蛋白酶-9(MMP-9)、D二聚体(D-D)、IL-6等指标低于对照组,IL-10高于对照组,差异具有统计学意义(P<0.05);治疗后观察组糖类抗原CA125低于对照组,CD4^(+)/CD8^(+)、CD4^(+)细胞高于对照组(P<0.05);治疗后观察组健康状况调查简表(SF-36)评分高于对照组,中医症状总积分低于对照组(P<0.05);观察组总有效率高于对照组[96.49%(55/57)vs 82.46%(46/57),P<0.05]。结论:对于慢性盆腔炎(湿热瘀结型)患者而言西医联合盆炎1号方经皮经穴靶向透药治疗有助于调控炎症因子,调节免疫功能,提高临床疗效。
Objective:To investigate the application value of Pelvic Inflammation No.1 formula of transdermal meridian pointtargeted drug delivery therapy in the treatment of patients with chronic pelvic inflammatory disease(damp-heat stasis type).Methods:All patients with chronic pelvic inflammatory disease(damp-heat stasis type)visited Danzhou Hospital of Traditional Chinese Medicine from August 2017 to March 2021 and were randomly grouped,57 patients in the control group were treated with simple Western medicine,and 57 patients in the observation group were combined with Pelvic Inflammation No.1 formula transdermal meridian targeted transdermal medication,and the therapeutic efficacies were compared after 3 months of treatment.Results:After treatment,serum matrix metalloproteinase-9(MMP-9),D dimer(D-D),IL-6 and other indexes in the observation group were lower than those in the control group,and IL-10 was higher than that in the control group,the difference was statistically significant(P<0.05).After treatment,the carbohydrate antigen CA125 in the observation group was lower than that in the control group,and the CD4^(+)/CD8^(+)and CD4^(+)cells in the observation group were higher than those in the control group(P<0.05).After treatment,the score of summary of health status surveys(SF-36)in the observation group was higher than that in the control group,and the total score of TCM symptoms was lower than that in the control group(P<0.05).The total effective rate in the observation group was 96.49%(55/57),which was higher than 82.46%(46/57)in the control group(P<0.05).Conclusion:For patients with chronic pelvic inflammatory disease(damp-heat stagnation type),combined with Pelvic Inflammation No.1 formula transdermal via acupoints targeted drug therapy can help to regulate inflammatory factors,regulate immune function,and improve clinical efficacy.
作者
冯强
陈红梅
唐瑞莲
吴玉青
余永燕
叶纪平
FENG Qiang;CHEN Hongmei;TANG Ruilian;WU Yuqing;YU Yongyan;YE Jiping(Department of Obstet-rics and Gynecology,Danzhou Hospital of Traditional Chinese Medicine,Hainan Province,Danzhou 571700,China;Traditional Chinese Medicine Clinic,China Academy of Chinese Medical Sciences,Beijing 100028,China;Internal Medicine Clinic of Wuxi Traditional Chinese Medicine Hospital,Wuxi 214071,China)
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2024年第8期1735-1739,共5页
Chinese Journal of Immunology
基金
海南省卫生计生行业科研项目(19A200190)。
关键词
盆炎1号方
经皮经穴靶向透药治疗
慢性盆腔炎
炎症因子
免疫功能
症状积分
生活质量
纤维化
Pelvic Inflammation No.1 formula
Percutaneous meridian-targeted drug penetration therapy
Chronic pelvic inflammatory disease
Inflammatory factors
Immune function
Symptom score
Quality of life
Fibrosis
